The findings, published in the journal Diabetes, Obesity and Metabolism, provide real-world context to previous randomized clinical trials indicating that patients who stopped semaglutide (sold under the brand names Ozempic/Wegovy) and tirzepatide (sold under the brand names Mounjaro/Zepbound) regained more than half of the weight they lost within 12 months
But here's the thing: the same effect that makes you feel full and satisfied is also what causes the side effects
Large-scale clinical trials have demonstrated that GLP-1RAs reduce the incidence of major adverse cardiovascular events (MACE), including myocardial infarction (MI) and stroke, through metabolic, anti-inflammatory, and direct cardiac mechanisms in both diabetic and non-diabetic populations [316,317,318]
The future of longevity medicine has arrived at the Center for Aesthetic Medicine
These medications are generally considered a long term, potentially lifelong treatment, as Yet, 32% of people who begin taking GLP-1 weight loss medications stop within a year due to several reasons, including the high cost and severity of side effects
